OptimizeRx vs Research Solutions
OPRX and RSSS side by side, both in miscellaneous business services. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How OPRX and RSSS compare
OptimizeRx is the larger company, worth 2.6 times as much as Research Solutions ($169M against $65.5M).
On earnings, Research Solutions is cheaper: it trades at 21.6× trailing earnings, against 37.3× for OptimizeRx.
Research Solutions grew revenue faster over the last twelve months (−1.5% versus −5.8% for OptimizeRx).
Research Solutions keeps more of each dollar of sales as profit, with a net margin of 5.8% compared with 4.7% at OptimizeRx.
Research Solutions scores higher on the StockData Score (14 against 10 for OptimizeRx), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | OPRX | RSSS |
|---|---|---|
| Size and price | ||
| Market cap | $169M | $65.5M |
| Share price | $8.95 | $1.94 |
| Change, 1 year | −45.8% | −37.8% |
| Change, 5 years | −87.5% | −19.5% |
| Beta (5Y) | 1.97 | 0.42 |
| Employees | 104 | 141 |
| StockData Score | ||
| Total score | 10 | 14 (better) |
| Valuation score | 2 | 4 (better) |
| Growth score | 2 | 2 |
| Performance score | 2 | 4 (better) |
| Health score | 4 | 4 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | 37.3× | 21.6× (better) |
| P/S | 1.7× | 1.4× (better) |
| P/B | 1.3× (better) | 3.2× |
| EV/EBITDA | 10.7× (better) | 10.9× |
| P/FCF | 9.2× (better) | 12.5× |
| PEG | – | 0.33 |
| FCF yield | 10.9% (better) | 8.0% |
| Fair value | $10.02 | $2.72 |
| Margin of safety | 10.7% | 28.7% (better) |
| Growth | ||
| Revenue growth (TTM) | −5.8% | −1.5% (better) |
| Revenue growth, 5Y average | 20.4% (better) | 8.8% |
| Net income growth (TTM) | – | 123% |
| EPS growth (TTM) | – | 125% |
| Profitability | ||
| Gross margin | 73.2% (better) | 51.9% |
| Operating margin | 11.1% (better) | 7.4% |
| Net margin | 4.7% | 5.8% (better) |
| FCF margin | 18.6% (better) | 10.8% |
| Return on equity | 3.7% | 16.3% (better) |
| Return on invested capital | 5.8% | 70.1% (better) |
| Financial health | ||
| Debt / equity | 0.15 (better) | 0.00 |
| Net debt / EBITDA | −0.33 | – |
| Interest coverage | 2.3× | – |
| Current ratio | 5.58 (better) | 0.83 |
| Altman Z-score | 3.50 (better) | 2.10 |
| Piotroski F-score | 8 (better) | 7 |
| Dividends and buybacks | ||
| Buyback yield | – | 0.08% |
| Shareholder yield | 0.00% | 0.08% (better) |
| Ownership | ||
| Held by institutions | 59.6% | 32.4% |
| Held by insiders | 19.4% | 14.0% |
| Insider net buying, 12 months | −$18.8K | – |
| Superinvestors holding | – | 1 |
| Short interest, % of float | 7.8% | 0.13% |
Go deeper
- OPRX stock overview
- OPRX income statement
- OPRX valuation and score
- RSSS stock overview
- RSSS income statement
- RSSS valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.